Bridgewater Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-6,452
| Closed | -$1.52M | – | 674 |
|
|
2024
Q4 | $1.52M | Buy |
6,452
+4,450
| +222% | +$1.05M | 0.01% | 467 |
|
|
2024
Q3 | $551K | Buy |
+2,002
| New | +$551K | ﹤0.01% | 681 |
|
|
2024
Q1 | – | Sell |
-1,951
| Closed | -$373K | – | 684 |
|
|
2023
Q4 | $373K | Buy |
1,951
+65
| +3% | +$12.4K | ﹤0.01% | 723 |
|
|
2023
Q3 | $334K | Buy |
1,886
+90
| +5% | +$15.9K | ﹤0.01% | 718 |
|
|
2023
Q2 | $341K | Buy |
1,796
+541
| +43% | +$103K | ﹤0.01% | 674 |
|
|
2023
Q1 | $251K | Buy |
+1,255
| New | +$251K | ﹤0.01% | 689 |
|
|
2022
Q4 | – | Sell |
-1,283
| Closed | -$257K | – | 823 |
|
|
2022
Q3 | $257K | Sell |
1,283
-229
| -15% | -$45.9K | ﹤0.01% | 835 |
|
|
2022
Q2 | $221K | Buy |
+1,512
| New | +$221K | ﹤0.01% | 967 |
|
|
2021
Q4 | – | Sell |
-2,234
| Closed | -$422K | – | 734 |
|
|
2021
Q3 | $422K | Sell |
2,234
-3,865
| -63% | -$730K | ﹤0.01% | 604 |
|
|
2021
Q2 | $1.03M | Buy |
+6,099
| New | +$1.03M | 0.01% | 581 |
|